Terms: = Prostate cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864
108 results:
1. In vitro and in vivo anti-tumor effect of Trichobakin fused with urokinase-type plasminogen activator ATF-TBK.
Pham DD; Pham TH; Bui TH; Britikova EV; Britikov VV; Bocharov EV; Usanov SA; Phan VC; Le TBT
Mol Biol Rep; 2024 Jan; 51(1):130. PubMed ID: 38236367
[TBL] [Abstract] [Full Text] [Related]
2. Cardiometabolic comorbidities in Hispanic/Latino cancer survivors: prevalence and impact on health-related quality of life and supportive care needs.
Maras AF; Penedo FJ; Ramirez AG; Worch SM; Ortiz MS; Yanez B; Munoz E; Lad T; Hollowell C; Medina HN; Moreno PI
Support Care Cancer; 2023 Nov; 31(12):711. PubMed ID: 37982906
[TBL] [Abstract] [Full Text] [Related]
3. Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade.
Beatrici E; Filipas DK; Stone BV; Labban M; Qian Z; Lipsitz SR; Lughezzani G; Buffi NM; Cole AP; Trinh QD
Urol Oncol; 2023 Dec; 41(12):483.e11-483.e19. PubMed ID: 37852818
[TBL] [Abstract] [Full Text] [Related]
4. Prediction of Resistance to
Sartor O; Ledet E; Huang M; Schwartz J; Lieberman A; Lewis B; Layton J; Barata P; Jang A; Hawkins M; Pocha O; Lanka S; Harris K
J Nucl Med; 2023 Nov; 64(11):1721-1725. PubMed ID: 37770113
[No Abstract] [Full Text] [Related]
5. Association between greenspace and cancer: evidence from a systematic review and meta-analysis of multiple large cohort studies.
Li J; Xie Y; Xu J; Zhang C; Wang H; Huang D; Li G; Tian J
Environ Sci Pollut Res Int; 2023 Aug; 30(39):91140-91157. PubMed ID: 37474858
[TBL] [Abstract] [Full Text] [Related]
6. prostate cancer genetic alterations in Hispanic men.
Arenas-Gallo C; Rhodes S; Garcia JA; Weinstein I; Prunty M; Lewicki P; Brant A; Basourakos SP; Barbieri CE; Lifschutz N; Schumacher FR; Shoag JE
Prostate; 2023 Sep; 83(13):1263-1269. PubMed ID: 37301735
[TBL] [Abstract] [Full Text] [Related]
7. Two unique BAP1 pathogenic variants identified in the same family by panel cascade testing.
Byrne L; Ingalls C; Ansari A; Porteus C; Donenberg TR; Sussman DA; Cebulla CM; Abdel-Rahman MH
Fam Cancer; 2023 Jul; 22(3):307-311. PubMed ID: 36513904
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive prostate cancer in the LATITUDE Study.
Koroki Y; Taguri M
Target Oncol; 2023 Jan; 18(1):119-128. PubMed ID: 36443540
[TBL] [Abstract] [Full Text] [Related]
9. Usefulness of grayscale values of hypoechoic lesions matched with target lesions observed on magnetic resonance imaging for the prediction of clinically significant prostate cancer.
Kim DG; Yoo JW; Koo KC; Chung BH; Lee KS
BMC Urol; 2022 Oct; 22(1):164. PubMed ID: 36309672
[TBL] [Abstract] [Full Text] [Related]
10. Intermediate-term oncological outcomes after a negative endorectal coil multiparametric MRI of the prostate in patients without biopsy proven prostate cancer.
Kamal O; Comerford J; Foster BR; Young DJ; Amling C; Coakley FV
Clin Imaging; 2022 Dec; 92():112-116. PubMed ID: 36306588
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of Apparent Diffusion Coefficient Value and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameters of prostate cancer Patients after Diagnosis and Treatment with Magnetic Resonance Imaging.
Gu P
Comput Math Methods Med; 2022; 2022():3111054. PubMed ID: 35785146
[TBL] [Abstract] [Full Text] [Related]
12. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
[TBL] [Abstract] [Full Text] [Related]
13. Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19.
So ACP; Karampera C; Khan M; Russell B; Moss C; Monroy-Iglesias MJ; Thillai K; Josephs DH; Pintus E; Rudman S; Van Hemelrijck M; Dolly S; Enting D
BMC Urol; 2022 Apr; 22(1):71. PubMed ID: 35488333
[TBL] [Abstract] [Full Text] [Related]
14. Role of Genetic Variations in
Híveš M; Jurečeková J; Kliment J; Grendár M; Kaplán P; Dušenka R; Evin D; Vilčková M; Holečková KH; Sivoňová MK
Cancer Genomics Proteomics; 2022; 19(3):362-371. PubMed ID: 35430569
[TBL] [Abstract] [Full Text] [Related]
15. Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer.
Henderson RH; Bryant CM; Nichols RC; Mendenhall WM; Hoppe BS; Su Z; Morris CG; Mendenhall NP
Acta Oncol; 2022 Apr; 61(4):468-477. PubMed ID: 34965846
[TBL] [Abstract] [Full Text] [Related]
16. Somatic Features of Response and Relapse in Non-muscle-invasive Bladder cancer Treated with Bacillus Calmette-Guérin Immunotherapy.
Bacon JVW; Müller DC; Ritch E; Annala M; Dugas SG; Herberts C; Vandekerkhove G; Seifert H; Zellweger T; Black PC; Bubendorf L; Wyatt AW; Rentsch CA
Eur Urol Oncol; 2022 Dec; 5(6):677-686. PubMed ID: 34895867
[TBL] [Abstract] [Full Text] [Related]
17. The role of testosterone replacement therapy and statin use, and their combination, in prostate cancer.
Lopez DS; Huang D; Tsilidis KK; Canfield S; Khera M; Baillargeon JG; Kuo YF; Peek MK; Platz EA; Markides K
Cancer Causes Control; 2021 Sep; 32(9):965-976. PubMed ID: 34041642
[TBL] [Abstract] [Full Text] [Related]
18. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer.
Song J; Ma S; Sokoll LJ; Eguez RV; Höti N; Zhang H; Mohr P; Dua R; Patil D; May KD; Williams S; Arnold R; Sanda MG; Chan DW; Zhang Z
Theranostics; 2021; 11(13):6214-6224. PubMed ID: 33995654
[No Abstract] [Full Text] [Related]
19. The Influence of Endogenous Testosterone on Incidental prostate cancer after Transurethral prostate Resection.
Porcaro AB; Siracusano S; Amigoni N; Tafuri A; Rizzetto R; Shakir A; Tiso L; Cerrato C; De Michele M; Bianchi A; Gallina S; Brunelli M; Migliorini F; Artibani W; Antonelli A
Urol Int; 2021; 105(9-10):826-834. PubMed ID: 33965959
[TBL] [Abstract] [Full Text] [Related]
20. Quantitative prostate MRI Analysis Following Fluvastatin Therapy for Localized prostate cancer - A Pilot Study.
Avery A; Sussman M; Longo J; Menezes RJ; Hamilton RJ; der Kwast THV; Fleshner NE; Penn LZ; Ghai S
Can Assoc Radiol J; 2021 Nov; 72(4):750-758. PubMed ID: 33563030
[TBL] [Abstract] [Full Text] [Related]
[Next]
